995 related articles for article (PubMed ID: 31017091)
41. Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer.
Tateishi U
Jpn J Clin Oncol; 2020 Apr; 50(4):349-356. PubMed ID: 32147685
[TBL] [Abstract][Full Text] [Related]
42. Lutetium
Emmett L; Willowson K; Violet J; Shin J; Blanksby A; Lee J
J Med Radiat Sci; 2017 Mar; 64(1):52-60. PubMed ID: 28303694
[TBL] [Abstract][Full Text] [Related]
43. The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation.
Miyahira AK; Soule HR
J Nucl Med; 2022 Mar; 63(3):331-338. PubMed ID: 34675109
[TBL] [Abstract][Full Text] [Related]
44. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
45. PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.
Eapen RS; Nzenza TC; Murphy DG; Hofman MS; Cooperberg M; Lawrentschuk N
World J Urol; 2019 Jul; 37(7):1255-1261. PubMed ID: 30374609
[TBL] [Abstract][Full Text] [Related]
46. PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.
Zschaeck S; Lohaus F; Beck M; Habl G; Kroeze S; Zamboglou C; Koerber SA; Debus J; Hölscher T; Wust P; Ganswindt U; Baur ADJ; Zöphel K; Cihoric N; Guckenberger M; Combs SE; Grosu AL; Ghadjar P; Belka C
Radiat Oncol; 2018 May; 13(1):90. PubMed ID: 29751842
[No Abstract] [Full Text] [Related]
47. [
Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
[TBL] [Abstract][Full Text] [Related]
48. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
49.
Werner RA; Derlin T; Lapa C; Sheikbahaei S; Higuchi T; Giesel FL; Behr S; Drzezga A; Kimura H; Buck AK; Bengel FM; Pomper MG; Gorin MA; Rowe SP
Theranostics; 2020; 10(1):1-16. PubMed ID: 31903102
[TBL] [Abstract][Full Text] [Related]
50. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
[TBL] [Abstract][Full Text] [Related]
51. EANM procedure guidelines for radionuclide therapy with
Kratochwil C; Fendler WP; Eiber M; Baum R; Bozkurt MF; Czernin J; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen W; Rahbar K; Schöder H; Virgolini I; Wester HJ; Bodei L; Fanti S; Haberkorn U; Herrmann K
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2536-2544. PubMed ID: 31440799
[TBL] [Abstract][Full Text] [Related]
52. A Prospective Comparison of
Harmon SA; Bergvall E; Mena E; Shih JH; Adler S; McKinney Y; Mehralivand S; Citrin DE; Couvillon A; Madan RA; Gulley JL; Mease RC; Jacobs PM; Pomper MG; Turkbey B; Choyke PL; Lindenberg ML
J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
[TBL] [Abstract][Full Text] [Related]
53. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy.
Capasso G; Stefanucci A; Tolomeo A
Eur J Med Chem; 2024 Jan; 263():115966. PubMed ID: 37992520
[TBL] [Abstract][Full Text] [Related]
54. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted
Werner RA; Sheikhbahaei S; Jones KM; Javadi MS; Solnes LB; Ross AE; Allaf ME; Pienta KJ; Lapa C; Buck AK; Higuchi T; Pomper MG; Gorin MA; Rowe SP
Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739
[TBL] [Abstract][Full Text] [Related]
55. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria.
Fanti S; Hadaschik B; Herrmann K
J Nucl Med; 2020 May; 61(5):678-682. PubMed ID: 31806774
[TBL] [Abstract][Full Text] [Related]
56. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.
Wester HJ; Schottelius M
Semin Nucl Med; 2019 Jul; 49(4):302-312. PubMed ID: 31227053
[TBL] [Abstract][Full Text] [Related]
57. Imaging of Prostate Cancer Using
Singh A; Kulkarni HR; Baum RP
PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453
[TBL] [Abstract][Full Text] [Related]
58. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
Maurer T; Gschwend JE; Eiber M
Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
[TBL] [Abstract][Full Text] [Related]
59. Radiolabeled prostate-specific membrane antigen small-molecule inhibitors.
Will L; Sonni I; Kopka K; Kratochwil C; Giesel FL; Haberkorn U
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):168-180. PubMed ID: 28217987
[TBL] [Abstract][Full Text] [Related]
60. Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response in Patients with Advanced Prostate Cancer.
Esen B; Herrmann K; Bavbek S; Kordan Y; Tilki D; Esen T
Eur Urol Focus; 2023 Jul; 9(4):596-605. PubMed ID: 36842919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]